Company Profile

Targacept Inc
Profile last edited on: 6/15/2021      CAGE: 4SEZ2      UEI: ER6HGKX8AFN5

Business Identifier: Neuronal nicotinic receptor technology
Year Founded
1997
First Award
2003
Latest Award
2003
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

100 North Main Street Suite 1510
Winston-Salem, NC 27101
   (336) 480-2100
   jo.peay@targacept.com
   www.targacept.com
Location: Single
Congr. District: 05
County: Forsyth

Public Profile

Initially launched by Rhone-Poulenc Rorer Inc. and RJR Nabisco Inc., Targacept was set up to work on compounds interactive with human nicotinic receptors. The declared objective was to develop and commercialize new drugs to treat Alzheimer's and Parkinson's diseases. In August 2015, Taracept did a reverse merger with Calatyst Biosciences Inc - also SBIR Involved with the combined entity retaining the Catalyst name replacing symbol TRGT by Catalyst symbol - CBIO providing partner Pfizer a shorcut to NASDAQ. With decades of research at R.J. Reynolds Tobacco Company (RJRT) into the chemistry and biology of nicotine resulting in hundreds of scientific papers and abstracts, many focused on neuronal nicotinic receptors (NNRs), a unique class of molecular targets in the body that maintain and adjust nervous system activity. The findings from RJRT’s research staff, as well as numerous investigations reported in the scientific literature into the biological effects of nicotine, suggested a role for NNRs in the treatment of human disease and commercial potential for RJR’s research. Targacept, Inc. was established as a wholly owned subsidiary of RJRT and was then spun out in August 2000. The spin-out allowed Targacept to combine its expertise in discovering new therapeutic agents with investors that have experience in the pharmaceutical business. Products in place to date are Inversine® (mecamylamine HCl) for the treatment of moderately severe to severe essential hypertension and for uncomplicated cases of malignant hypertension

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
20-24
Revenue Range
2M-2.5M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : TRGT
IP Holdings
150-249

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2003 1 NSF $99,959
Project Title: The Development of Self-Organizing Maps for Drug Discovery

Key People / Management

  Stephen A H Hill -- Chief Exec. Officer, Pres And Director

  J Donald Debethizy -- former President

  Jeffrey Schmitt